Non-invasive intranasal delivery of small molecules, proteins, peptides and stem cells exploits the olfactory and trigeminal neuronal pathways to bypass the Blood Brain Barrier and deliver the therapeutic directly to the brain. Intranasal administration of therapeutics for the treatment of CNS and neurodegenerative disorders such as brain tumors, HIV encephalopathy, epilepsy, Parkinson’s, Huntington, Alzheimer’s and Traumatic Brain Injury offer compelling benefits for the patient. Mystic optimized intranasal delivery systems are designed to simplify intracranial administration for both caregiver and the patient, minimize systemic exposure and enable rapid CNS delivery of the therapeutic.

Key performance features of all our VersiDoser® and VRx2™ nasal delivery solutions include:

• Precise dosing that can be calibrated to a specified dose volume
• Unit dose aseptic packaging for preservative free formulations
• Primary containers can be terminally sterilized if required
• Side actuation dispenser device for ease of use
• No device priming required
• User independent device actuation
• Dose counter
• Configurable spray plume (stream, spray, aerosolized spray)
• Metal free fluid delivery path
• Tamper resistant packaging
• “Lock Up” design to prevent mis-use or re-purposing after use
• Compact design form factor making the device easy to store, transport and carry
• Intuitive design and operation facilitates first use
• Commercially scalable, cost efficient design for manufacturing

ArcherFish™ N2B